BASF weighs a higher bid for Evonik stock before November 3 results

Published on 10/15/2026 at 11:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Berenberg lifted target to EUR 20.00 from EUR 15.50 on October 5, 2026. Evonik stock costs EUR 21.03 on October 15, 2026, 0.52 percent below Xetra close.

Takeover and operating markers

BASF is considering a higher bid after its EUR 22.15 approach was rejected on September 25, 2026.
Evonik's adjusted EBITDA reached EUR 630 million in the second quarter of 2026, up 24 percent year over year.
Evonik stock trades at EUR 21.03 at 11:07 a.m. CEST at Lang & Schwarz on October 15, 2026, 0.52 percent below the Xetra close of October 14, 2026.
Parmantier & Cie. set a EUR 20.50 target and a Hold rating on October 6, 2026.

Schwarzweiß-Reportagebild von Industriearbeitern bei der Inspektion chemischer Reaktorbehälter — Evonik Industries DE000EVNK013 in einer dokumentarischen Schwarzweiß-Reportage von Arbeitern an industriellen Chemikalienbehältern, Illustration mit AI erstellt.

Evonik (ISIN DE000EVNK013) was trading at EUR 21.03 at Lang & Schwarz on October 15, 2026 at 11:07 a.m. CEST, 0.52 percent below the Xetra close of October 14, 2026 at EUR 21.14. BASF is willing to revisit its bid after due diligence, according to Aktiencheck on October 15, 2026. The report said Evonik had rejected an opening proposal of EUR 22.15 per share as too low.

Takeover terms remain unsettled

The bid remains exploratory rather than an agreed transaction. EQS News reported on September 25, 2026 that Evonik confirmed receipt of a non-binding approach from BASF. The same source identified the approach as a potential takeover offer, not a completed deal.

The chronology shows how quickly the valuation debate changed. On September 25, 2026, Evonik disclosed the EUR 22.15 approach. On October 5, 2026, Yahoo Finance reported that Berenberg raised its rating from Sell to Hold and its target from EUR 15.50 to EUR 20.00. On October 15, 2026, the BASF report put renewed due diligence at the center of the next step.

What does the bid mean for earnings?

The operating test arrives with Evonik's third-quarter report. A Yahoo Finance transcript said adjusted EBITDA rose 24 percent year over year to EUR 630 million in the second quarter of 2026, while the company described Advanced Technologies and methionine as important drivers. That result gives the takeover debate an operating benchmark, but the next report will show whether the improvement continued.

Dates frame the next decision

Evonik's investor-relations calendar lists the third-quarter 2026 results for November 3, 2026. The same calendar schedules fourth-quarter 2026 reporting for March 4, 2027. The November release is the nearer date for testing the earnings basis behind any renewed bid.

Stock remains below the opening bid

At EUR 21.03, the Lang & Schwarz quote remains below BASF's reported EUR 22.15 opening proposal while sitting within the EUR 12.49 to EUR 21.84 52-week range. Parmantier & Cie. assigned Evonik a Hold rating and a EUR 20.50 six-month target on October 6, 2026, according to EQS News. The contrast leaves investors weighing takeover optionality against the next operating update. Evonik stock was trading at EUR 21.03 at Lang & Schwarz on October 15, 2026 at 11:07 a.m. CEST, 0.52 percent below the Xetra close of October 14, 2026 at EUR 21.14. The further course of trading is shown by the continuously updated real-time quote of Evonik stock.